In 2024, TWM interviewed tissue mill executives in Latin America, India, Indonesia, the United Kingdom, Africa, and Türkiye for Country Reports. One year on, we revisit a selection of the leading companies to assess their progress.
INDIA
Jani Sales: “Full steam ahead” as PM2 reaches full capacity and India’s tissue market strengthens
TWM interviewed Jani Sales’ Director Abiali Jani in December 2024, for the magazine’s India Country Report. The Sarigam-headquartered, family-run company – led by Saifee Jani and his sons Abiali, Abizer and Abilfazal – had most recently further expanded its tissue production capacity at its Sarigam mill to 18,000tpy, after starting up a Baosuo-supplied tissue machine in October 2024.
Jani had said the local Indian market was “looking very promising”, with a “consistent growth trajectory – the tissue industry in India is growing in double digits, driven by factors such as changing buying patterns and the growing influence of the younger population.”
Over the next decade, India’s tissue paper market is projected to experience substantial growth, with a compound annual growth rate (CAGR) exceeding 12% during the forecast period. Growth that is primarily driven by the growing demand from institutional consumers such as hotels, restaurants, and hospitals, he had said.
Now in June 2025, and Jani says it is “full steam ahead” as PM2 reaches full capacity and India’s tissue market strengthens. The company has made significant strides in both operational capacity and market presence: most notably, development has been the successful ramp-up of PM2 at the Sarigam mill, which has now reached full capacity. The machine is designed for 100% virgin pulp-based tissue production, and the business says it has proven to be a strategic asset, and a testament to its commitment to innovation, sustainability, and quality.
PM2 has boosted the group’s total capacity to 53,000 tonnes per year, and also solidified Jani Sales’ position as a major player in the Indian tissue industry: “The ramp up was completed ahead of schedule, and the machine is now consistently producing high-quality tissue that meets both domestic and export standards,” the company said.
The growth has been organic and deliberate: “We’ve never rushed into expansion for the sake of numbers. PM2 has been a game-changer for us, and it reflects our belief in calculated, quality-focused growth.”
On the broader market front, the Indian tissue sector continues to display robust growth. Domestic demand remains strong, buoyed by increasing hygiene awareness and urbanisation. Internationally, with the United States imposing tariffs on several competing regions and India potentially finalising a trade agreement with the US, Indian tissue exporters are finding more open doors abroad.
“India is emerging as a key alternative for tissue supply, particularly to markets like the U.S. that are looking for quality products from stable trade partners,” the company says. “This is an opportunity we are closely monitoring.”
Looking ahead to the rest of 2025 and into 2026, Jani Sales says it is maintaining its disciplined approach to growth. While no immediate announcements on new machinery have been made, various options to expand capacity and enhance efficiency are under consideration.
“Our core strategy is simple organic growth with an uncompromising focus on quality,” the company said. “We’re reviewing multiple aspects of the market to determine how best to position ourselves for the future. Whether it’s new machinery, process optimisation, or stronger international market integration, we’re prepared to make the right investments at the right time.”
As the global tissue industry continues to evolve, Jani Sales remains steadfast in its mission to be India’s leading name in high-quality tissue production. With PM2 operating at full capacity and strategic evaluations underway, the company is well-positioned for its next chapter of sustainable growth.
